Fulcrum Therapeutics, Inc., founded in Cambridge, Massachusetts, is dedicated to developing and distributing transformative gene regulation drugs. The company's core mission is to modulate gene expression to treat the root cause of genetically defined diseases, particularly in areas with high unmet medical needs. Fulcrum's lead program, losmapimod, is currently being investigated in clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Notable affiliated individuals include key scientists and industry leaders who have contributed to the company's innovative approach to gene regulation. Fulcrum has attracted significant investment from prominent venture capital firms specializing in biotech. The company has achieved critical milestones in advancing its clinical trials and has made a substantial impact on the healthcare sector by addressing previously untreatable genetic conditions.
